Trial Profile
A Retrospective Study to Investigate the Effect of Bupivacaine Liposomal Injectable Suspension (BLIS) on Opioid Use, Hospital Length of Stay, Discharge Status and Hospitalization Costs in Patients Undergoing Total Hip Arthroplasty (THA) at High Use Hospitals
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Jul 2019
Price :
$35
*
At a glance
- Drugs Bupivacaine (Primary)
- Indications Postoperative pain
- Focus Therapeutic Use
- 12 Jun 2019 Primary endpoint (Home discharge status: BLIS compared to control (in both the Medicare and commercial insurance groups)) has been met, according to results presented in a Pacira BioSciences media release.
- 12 Jun 2019 Primary endpoint (Hospital length of stay (LOS): BLIS compared to control (in both the Medicare and commercial insurance groups)) has been met, according to results presented in a Pacira BioSciences media release.
- 12 Jun 2019 According to a Pacira BioSciences media release, new data from this study were published in The Journal of Medical Economics.